(NASDAQ: PTCT) Ptc Therapeutics's forecast annual revenue growth rate of 0.78% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.85%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.43%.
Ptc Therapeutics's revenue in 2024 is $900,454,000.On average, 6 Wall Street analysts forecast PTCT's revenue for 2024 to be $56,298,953,843, with the lowest PTCT revenue forecast at $54,100,768,761, and the highest PTCT revenue forecast at $57,710,820,059. On average, 6 Wall Street analysts forecast PTCT's revenue for 2025 to be $56,268,261,099, with the lowest PTCT revenue forecast at $42,246,754,164, and the highest PTCT revenue forecast at $65,100,925,071.
In 2026, PTCT is forecast to generate $73,821,587,451 in revenue, with the lowest revenue forecast at $50,585,334,192 and the highest revenue forecast at $91,429,760,737.